Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma

Abstract EN

Background.

The aim of this study is to identify possible prognostic-related immune genes in bladder urothelial carcinoma and to try to predict the prognosis of bladder urothelial carcinoma based on these genes.

Methods.

The Cancer Genome Atlas (TCGA) expression profile data and corresponding clinical traits were obtained.

Differential gene analysis was performed using R software.

Reactome was used to analyze the pathway of immune gene participation.

The differentially expressed transcription factors and differentially expressed immune-related genes were extracted from the obtained list of differentially expressed genes, and the transcription factor-immune gene network was constructed.

To analyze the relationship between immune genes and clinical traits of bladder urothelial carcinoma, a multifactor Cox proportional hazards regression model based on the expression of immune genes was established and validated.

Results.

Fifty-eight immune genes were identified to be associated with the prognosis of bladder urothelial carcinoma.

These genes were enriched in Cytokine Signaling in Immune System, Signaling by Receptor Tyrosine Kinases, Interferon alpha/beta signaling, and other immune related pathways.

Transcription factor-immune gene regulatory network was established, and EBF1, IRF4, SOX17, MEF2C, NFATC1, STAT1, ANXA6, SLIT2, and IGF1 were screened as hub genes in the network.

The model calculated by the expression of 16 immune genes showed a good survival prediction ability (p<0.05 and AUC = 0.778).

Conclusion.

A transcription factor-immune gene regulatory network related to the prognosis of bladder urothelial carcinoma was established.

EBF1, IRF4, SOX17, MEF2C, NFATC1, STAT1, ANXA6, SLIT2, and IGF1 were identified as hub genes in the network.

The proportional hazards regression model constructed by 16 immune genes shows a good predictive ability for the prognosis of bladder urothelial carcinoma.